Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $28.83.

Several brokerages have recently issued reports on IMNM. Piper Sandler decreased their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Finally, Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an "overweight" rating and a $30.00 target price for the company.

Immunome Price Performance

NASDAQ:IMNM traded up $0.38 during mid-day trading on Tuesday, reaching $11.53. The stock had a trading volume of 1,014,805 shares, compared to its average volume of 780,808. Immunome has a 12 month low of $6.93 and a 12 month high of $30.96. The stock has a market capitalization of $719.70 million, a PE ratio of -1.42 and a beta of 1.82. The stock has a 50-day simple moving average of $12.49 and a two-hundred day simple moving average of $13.55.

Insiders Place Their Bets

In other Immunome news, CEO Clay B. Siegall purchased 66,057 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was purchased at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the transaction, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. The trade was a 15.74 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Philip Tsai purchased 21,000 shares of the company's stock in a transaction dated Thursday, November 21st. The shares were acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the purchase, the chief technology officer now directly owns 21,000 shares of the company's stock, valued at approximately $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 102,862 shares of company stock valued at $978,045 in the last 90 days. Corporate insiders own 8.60% of the company's stock.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in shares of Immunome in the 2nd quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Immunome in the second quarter valued at approximately $97,000. Arizona State Retirement System increased its position in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock valued at $131,000 after purchasing an additional 918 shares during the period. Intech Investment Management LLC bought a new position in Immunome during the 3rd quarter worth approximately $219,000. Finally, AQR Capital Management LLC lifted its position in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after purchasing an additional 4,129 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.